Partnership Opportunities
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at sponsor@hansonwade.com
Drive the Future of T-Cell Engagers at the 7th T-Cell Engager Summit
The T-cell engager field reached a turning point, with recent approvals, groundbreaking deals, and surging investment shaping the next generation of cancer immunotherapies. Biotech and pharma leaders advanced first-in-class, safe, and highly efficacious therapies, pushing toward the next major regulatory breakthrough.
C-level executives, VPs, and directors from across the industry came together to tackle key challenges, including enhancing therapeutic potency, mitigating on-target, off-tumor toxicity, optimizing drug constructs, and improving durability of response. Companies actively sought partnerships with CROs, CDMOs, CRS assay providers, and antibody discovery experts to accelerate discovery, optimize clinical translation, and de-risk first-in-human studies.
With T-cell engagers redefining immunotherapy, the summit served as a vital platform to shape the competitive landscape, drive innovation, and forge lasting partnerships.
Why Partner With Us in 2026?
Lead the Advancement of T-Cell Engager Therapeutics by contributing to next-generation construct design, optimizing bispecific formats, and enhancing clinical translation
Showcase Novel Solutions in TCE engineering, safety profiling, and potency optimization to a highly specialized audience
Forge Strategic Collaborations with biotech innovators and pharma leaders to accelerate clinical development and regulatory success
Demonstrate Expertise in Safety & Efficacy by addressing CRS mitigation, optimizing tumor selectivity, and refining co-stimulatory strategies for improved patient outcomes
Who Was in The Room?
